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AbstrACt
Objectives Lipid profiles are altered by active disease 
in patients with rheumatoid arthritis (rA) and may 
be further modified by treatment with Janus kinase 
inhibitors and other disease-modifying antirheumatic 
drugs.
Methods Lipid data were analysed from phase II 
and III studies of 4 mg (n=997) and 2 mg (n=479) oral 
baricitinib administered once daily in patients with 
moderate-to-severe active rA. Lipoprotein particle size 
and number and GlycA were evaluated with nuclear 
magnetic resonance in one phase III study. the effect of 
statin therapy on lipid levels was evaluated in patients on 
statins at baseline and in patients who initiated statins 
during the study.
results treatment with baricitinib was associated 
with increased levels of total cholesterol, low-density 
lipoprotein cholesterol (LdL-C), high-density lipoprotein 
cholesterol (HdL-C) and triglycerides, but no significant 
change in LdL-C:HdL-C ratio. Lipid levels plateaued after 
12 weeks of treatment. Baricitinib treatment increased 
large LdL and decreased small, dense LdL particle 
numbers and GlycA. Lipid changes from baseline were 
not significantly different between baseline statin users 
and non-users. In patients who initiated statin therapy 
during the study, LdL-C, triglycerides (baricitinib 4 mg 
only) and apolipoprotein B decreased to pre-baricitinib 
levels; HdL-C and apolipoprotein A-I levels remained 
elevated.
Conclusions Baricitinib was associated with increased 
LdL-C, HdL-C and triglyceride levels, but did not alter the 
LdL-C:HdL-C ratio. Evaluation of cardiovascular event 
rates during long-term treatment is warranted to further 
characterise these findings and their possible clinical 
implications.
trial registration number nCt00902486, 
nCt01469013, nCt01185353, nCt01721044, 
nCt01721057, nCt01711359, nCt01710358, 
nCt01885078.
IntrOduCtIOn
Baricitinib, an oral selective inhibitor of Janus 
kinase (JAK) 1 and JAK 2,1 is approved in the Euro-
pean Union and Japan for the treatment of moder-
ate-to-severe active rheumatoid arthritis (RA) in 
adults. Baricitinib improved signs and symptoms 
of RA in phase III, placebo and active-controlled 
studies in patients with active RA who were naïve 
to conventional synthetic disease-modifying 
antirheumatic drugs (csDMARD; RA-BEGIN),2 
or had an inadequate response (IR) to previous 
treatment with methotrexate (MTX; RA-BEAM),3 
csDMARDs (RA-BUILD)4 and biological DMARDs 
(RA-BEACON).5 
In RA, the proinflammatory state in untreated 
patients is associated with a decrease in total choles-
terol, low-density lipoprotein cholesterol (LDL-C) 
and high-density lipoprotein cholesterol (HDL-
C)6; anti-inflammatory therapies have been shown 
to increase these lipid levels.7–11 Increases in lipids 
persisted in a phase II study of baricitinib.12 The 
increase in LDL-C was associated with an increase 
in large and a decrease in small LDL, without any 
increase in LDL particle number. The increase in 
HDL-C was associated with an increase in HDL 
particle number across all particle sizes.12 This LDL 
and HDL particle profile has been associated with 
reduced atherogenic risk.13
This analysis assessed the effects of baricitinib 
on the lipid profile, lipoprotein particle size and 
number, and GlycA. GlycA, a measure of glyco-
sylated acute phase proteins, is an emerging inflam-
matory marker that may be useful for assessing 
disease activity and is associated with subclinical 
cardiovascular disease in patients with RA.14–19 
In addition, the effect of statin therapy on these 
biomarkers was evaluated. The impact of lipid 
alteration on cardiovascular risk, changes in risk 
scores and association between LDL-C change and 
major adverse cardiovascular events (MACE) were 
also assessed.
MethOds
study design and patients
Data were included from seven randomised clinical 
studies: three phase II (JADA, JADC and JADN) 
and four phase III studies (RA-BEGIN, RA-BEAM, 
RA-BUILD and RA-BEACON), including data from 
the long-term extension (LTE) (RA-BEYOND; data 
through 1 January 2016). All patients completing 
phase III studies or JADA were eligible to enter 
RA-BEYOND. The designs for each study have been 
previously described2–5 20–23 and are summarised in 
online supplementary table S1.
Each study was conducted in accordance with the 
principles of the Declaration of Helsinki and Good 
Clinical Practice Guidelines. All patients provided 
written informed consent. The studies were designed 
by the sponsors, Eli Lilly and Company and Incyte, 
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with input from an academic advisory board in which non-Lilly 
authors of this manuscript participated. All authors participated 
in the preparation and review of this manuscript and approved 
the final version.
data sets
Three data sets are defined: the six-study placebo-controlled 
set, the long-term baricitinib cohort and the all-baricitinib 
RA-MACE set. The six-study set included all phase II/III studies 
with placebo and baricitinib 4 mg treatment arms (JADA, JADC 
and JADN; and RA-BEAM, RA-BUILD and RA-BEACON; JADA, 
JADN, RA-BUILD and RA-BEACON also had a baricitinib 2 mg 
treatment arm  (online supplementary table S1)). The six-study 
set included data up to week 24 that were censored at rescue 
or the end of the placebo-controlled period. The long-term 
baricitinib cohort comprised patients randomised to baricitinib 
4 mg in RA-BEAM, RA-BUILD and RA-BEACON, and patients 
randomised to baricitinib 2 mg in RA-BUILD and RA-BEACON, 
including data from RA-BEYOND, with data censored at dose 
change or rescue in the LTE. The all-baricitinib RA-MACE set 
included all patients from the phase III studies, including patients 
in the LTE who received at least one baricitinib dose.
Lipid profile
Standard lipid panel (total cholesterol, LDL-C, HDL-C and 
triglycerides) was assessed for all studies; apolipoprotein A-I and 
apolipoprotein B for JADA and all phase III studies including 
the LTE; and nuclear magnetic resonance (NMR) spectroscopy 
panel (lipoprotein particles and GlycA) for JADA and RA-BEAM.
Serum samples for lipid profile were collected in a fasting state 
at baseline and weeks 12 and 24 after randomisation; results are 
reported from pooled data of the six-study placebo-controlled 
set. In the phase III studies, LDL-C was quantified by direct 
method; in the phase II studies, LDL-C was calculated using the 
Friedewald equation, unless triglycerides were >4.52 mmol/L, 
then LDL-C was quantified by direct method. Lipid treat-
ment-emergent highest values are reported based on criteria 
from the National Lipids Association Guidelines.24 Lipid profile 
up to 104 weeks was evaluated using the long-term baricitinib 
cohort.
nMr analysis
Determination of lipoprotein particle subfractions by NMR 
was assessed in RA-BEAM, with fasting serum samples collected 
at baseline and week 12 (LipoScience, now LabCorp, Morris-
ville, NC). Diameter ranges (nm) were 21.2‒23 for large LDL, 
18‒21.2 for small LDL, 8.8‒13 for large HDL, 8.2‒8.8 for 
medium HDL and 7.3‒8.2 for small HDL, as determined by 
the LP2 algorithm.25 Apolipoprotein A-I and apolipoprotein B 
serum samples were analysed at baseline and weeks 4 and 12 and 
were quantified using conventional ELISA (Pacific Biomarkers, 
Seattle, WA). GlycA levels were quantified by NMR in JADA 
and RA-BEAM at baseline and weeks 12 and 24 as previously 
described.14
statin use
Lipid effects by baseline statin use were evaluated in the 
six-study placebo-controlled set; data are presented for the 
placebo and baricitinib combined 2/4 mg groups. Lipid effects 
for patients who initiated statins during studies were evaluated 
in the six-study set for patients randomised to placebo and in the 
long-term cohort for patients randomised to baricitinib (2 and 
4 mg groups presented separately).
Cardiovascular risk assessment
To evaluate the risk of cardiovascular disease, the Framingham 
Risk Score26 and Reynolds Risk Score27 28 were assessed at base-
line and week 24 in the phase III studies. Relationships were 
explored in the all-baricitinib RA-MACE set between change in 
LDL-C and MACE, a composite measure that includes cardio-
vascular death, stroke and myocardial infarction. An indepen-
dent, external clinical endpoint committee adjudicated all death 
and potential cardiovascular events.
statistical analysis
Conventional lipid profiles including apolipoprotein A-I and 
apolipoprotein B were assessed using analysis of covariance 
(ANCOVA), adjusting for baseline value, study and treatment 
of analysed lipid measures. The long-term LDL-C and HDL-C 
profiles were analysed using a restricted maximum likeli-
hood-based mixed model for repeated measures, which included 
treatment, visit and the treatment-by-visit interaction as fixed 
categorical effects, and baseline as fixed continuous effect to 
estimate change from baseline across postbaseline visits after 
modelling three covariance structures (the heterogeneous autore-
gressive, compound symmetry and the Toeplitz) and selecting 
the variance-covariance structure with the smallest Akaike infor-
mation criterion. ANCOVA was also used to assess the NMR 
lipoprotein particle parameters and GlycA in RA-BEAM.
For patients who initiated statins during the study, lipid values 
were evaluated at baseline, initiation of statin therapy and the 
end of statin treatment or the analysis period. Analysis of vari-
ance containing explanatory terms for study and treatment was 
used. In addition, a subgroup analysis for change from baseline 
in total cholesterol, LDL-C, HDL-C and triglycerides based 
on subgroups defined by baseline statin use was performed 
using an ANCOVA model, with explanatory terms for baseline 
value, study, treatment, subgroup and treatment-by-subgroup 
interaction.
The Framingham Risk Score and Reynolds Risk Score were 
examined from each phase III study using ANCOVA, which 
included treatment and the baseline measurement as indepen-
dent variables, and change from baseline as the dependent vari-
able. The association between MACE and LDL-C change was 
examined using a waterfall plot. The waterfall plot was gener-
ated with each individual patient’s change of LDL-C from base-
line to maximum postbaseline measure, with data censored at 
treatment discontinuation, or statin therapy initiation or statin 
therapy change. Changes in LDL-C were ordered from right 
to left, representing the maximum decrease on the left end and 
maximum increase on the right end.
resuLts
Baseline demographics and disease characteristics of patients 
from the six-study placebo-controlled set, RA-BEAM and the 
all-baricitinib RA data were generally comparable among treat-
ment groups (table 1). Vital signs including blood pressure, pulse 
rate, weight and waist circumference were comparable among 
treatment groups (data not shown). In the all-baricitinib RA 
data, 37% of patients had a medical history of hypertension, 
6% had diabetes at baseline and 31% were obese (≥30 kg/m²). 
Previous studies of the phase III trials reported small increases in 
creatinine with baricitinib treatment.2–5
Lipid profile
In the six-study placebo-controlled set, baricitinib was 
associated with dose-dependent increases across all lipid 
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measures from baseline to week 12. Levels remained stable 
across groups from week 12 to 24. Per cent increases were 
similar from baseline to both weeks 12 and 24 (figure 1). 
There was no significant change in the LDL-C:HDL-C 
ratio from baseline at week 12 (placebo=−0.02, baric-
itinib 2 mg=−0.03, baricitinib 4 mg=−0.02) or week 24 
(placebo=−0.03, baricitinib 2 mg=−0.04, baricitinib 4 
mg=−0.01). After the initial increase from baseline to week 
12 in patients receiving baricitinib 4 mg, LDL-C and HDL-C 
remained stable through week 104 (online supplementary 
figure S1).
Correlation analyses with disease activity measures in the 
baricitinib 2 mg/4 mg analysis set revealed weak correlations 
between lipid changes and disease activity (online supplementary 
table S2). In patients treated with baricitinib in the RA-BEAM 
study, increases in LDL-C and HDL-C were correlated with 
table 1 Baseline demographics and disease characteristics in the six-study placebo-controlled set, RA-BEAM, and the all-baricitinib RA set
six-study placebo-controlled set rA-beAM
All-baricitinib rA
(n=3492)*
Placebo
(n=1070)
baricitinib 4 mg
(n=997)
baricitinib 2 mg
(n=479)
Placebo
(n=488)
baricitinib 4 mg
(n=487)
Adalimumab
(n=330)
Age, years 52.9 (11.9) 53.7 (12.0) 53.2 (12.0) 53.4 (11.8) 53.5 (12.2) 52.9 (12.3) 52.9 (12.2)
≥65 years of age, n (%) 173 (16) 199 (20) 82 (17) 82 (17) 103 (21) 56 (17) 612 (18)
BMI, kg/m2 27.8 (7.1) 28.0 (6.8) 29.0 (7.4) 26.7 (6.3) 26.8 (5.8) 26.4 (5.4) 27.7 (6.7)
Tobacco use, yes, n (%) 198 (19) 196 (20) 84 (18) 103 (21) 109 (22) 74 (22) 663 (20)
Female, n (%) 862 (81) 794 (80) 386 (81) 382 (78) 375 (77) 251 (76) 2760 (79)
Duration of RA†, years 8.9 (8.4) 8.9 (8.6) 9.0 (8.1) 8.9 (8.0) 8.7 (8.6) 8.3 (7.9) 7.7 (8.2)
Region, n (%)
  USA/Canada 240 (22) 225 (23) 162 (34) 39 (8) 40 (8) 26 (8) 840 (24)
  Central/South America and Mexico 203 (19) 197 (20) 54 (11) 141 (29) 143 (29) 96 (29) 701 (20)
  Asia (excluding Japan) 84 (8) 83 (8) 38 (8) 48 (10) 48 (10) 33 (10) 226 (7)
  Japan 156 (15) 132 (13) 36 (8) 93 (191) 93 (19) 63 (19) 514 (15)
  European Union 263 (25) 246 (25) 125 (26) 116 (24) 114 (23) 78 (24) 783 (22)
  Rest of the world 124 (12) 114 (11) 64 (13) 51 (11) 49 (10) 34 (10) 428 (12)
hsCRP (mg/L), median (first, third quartiles) 9.9 (4.8, 24.4) 10.7 (5.6, 25.4) 9.3 (4.9, 23.1) 12.7 (6.1, 26.8) 13.6 (6.6, 30.4) 14.4 (7.2, 29.8) 9.1 (4.1, 22.1)*
ESR, mm/hour 46.2 (24.9) 46.0 (25.1) 43.8 (22.3) 49.2 (26.1) 49.3 (25.8) 48.4 (25.6) 42.4 (25.4)*
DAS28-ESR 6.34 (0.99) 6.38 (0.96) 6.40 (0.99) 6.4 (1.0) 6.5 (0.9) 6.4 (1.0) 5.7 (1.5)*
DAS28-hsCRP 5.63 (0.95) 5.69 (0.94) 5.69 (0.96) 5.7 (1.0) 5.8 (0.9) 5.8 (0.9) 5.1 (1.5)*
Data are mean (SD) unless otherwise stated.
*The n for the all-baricitinib RA group for disease activity characteristics is 3439; it is smaller than the n for baseline demographics because efficacy baseline measures are only available for 
phase II/III studies; efficacy baseline measures were not available for a phase I RA study.
†Time from RA diagnosis.
BMI, body mass index; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; hsCRP, high-sensitivity C-reactive protein; RA, rheumatoid arthritis.
Figure 1 Lipid profile for total cholesterol, LDL-C, HDL-C, triglycerides, apolipoprotein A-I and apolipoprotein B in patients from the six-study 
placebo-controlled set. Data in line graphs are absolute values at baseline, week 12 and week 24 with data censored at rescue; mean (SD) for all 
lipids except triglycerides, which are median (25th, 75th percentiles). Patients on placebo who were rescued to baricitinib before week 24 were not 
included in this analysis. Inset bar charts show mean per cent change from baseline to weeks 12 and 24 with data censored at rescue. *P≤0.05, 
***P≤0.001 versus placebo. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 
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reductions in high-sensitivity C-reactive protein (hsCRP) and 
GlycA (online supplementary figure S2).
Lipid treatment-emergent highest values
Baseline abnormal LDL-C values (high or very high) were 11.8% 
in the placebo, 10.5% in the baricitinib 4 mg group and 8.7% 
in the baricitinib 2 mg group. Among patients in the barici-
tinib 4 mg group with a treatment-emergent increase in LDL-C, 
92% of patients did not reach the maximum LDL-C cate-
gory of ≥4.91 mmol/L, and 99% did not reach the maximum 
triglyceride category of ≥5.64 mmol/L (online supplementary 
table S3).
Changes in the nMr lipoprotein profile and GlycA
In RA-BEAM, there was a significant increase from base-
line to week 12 in mean LDL-C in the baricitinib 4 mg group 
(0.42 mmol/L) and adalimumab group (0.20 mmol/L) compared 
with placebo (−0.06 mmol/L, P=0.001) and in mean HDL-C 
(baricitinib 4 mg, 0.24 mmol/L; adalimumab 0.10 mmol/L; 
placebo 0.00 mmol/L; P=0.001). Statistically significant 
increases in large LDL particle numbers and decreases in small 
LDL particle numbers were observed in baricitinib and adali-
mumab arms compared with placebo (table 2). There was a 
statistically significant increase in total LDL particle numbers in 
baricitinib compared with placebo. The increases in large LDL 
table 2 NMR lipoprotein profile: particle subfractions and GlycA in RA-BEAM
Placebo
n=488
baricitinib 4 mg
n=487
Adalimumab
n=330
Mean number of particles (nmol/L)
  total LdL
   Baseline 1178.60 (398.50) 1178.16 (335.46) 1165.15 (330.16)
   Change from baseline at week 12 −21.31 (12.25) 15.77 (12.09)*++ −36.64 (14.77)
   Large LDL
   Baseline 513.31 (216.87) 506.54 (225.29) 501.96 (227.72)
   Change from baseline at week 12 −0.72 (8.20) 81.74 (8.09)***+++ 39.49 (9.89)**
   Small LDL
   Baseline 632.45 (415.25) 637.68 (374.39) 633.34 (372.48)
   Change from baseline at week 12 −21.86 (15.09) −80.26 (14.89)** −82.86 (18.18)**
    Medium small LDL
   Baseline 127.25 (83.21) 130.05 (77.97) 128.35 (77.36)
   Change from baseline at week 12 −3.18 (3.15) −16.29 (3.11)** −15.47 (3.80)*
    Very small LDL
   Baseline 505.26 (333.70) 507.64 (298.81) 504.94 (297.13)
   Change from baseline at week 12 −18.76 (12.07) −63.93 (11.91)** −67.37 (14.55)*
  total hdL
   Baseline 28.88 (5.90) 28.69 (5.96) 28.48 (5.84)
   Change from baseline at week 12 0.06 (0.22) 4.73 (0.21)***+++ 1.93 (0.26)***
   Large HDL
   Baseline 9.01 (3.41) 9.13 (3.48) 8.91 (3.56)
   Change from baseline at week 12 0.00 (0.12) 0.98 (0.12)***++ 0.41 (0.14)*
   Medium HDL
   Baseline 2.82 (3.27) 2.68 (3.01) 2.89 (3.27)
   Change from baseline at week 12 0.13 (0.14) 0.63 (0.14)*+++ −0.30 (0.17)*
   Small HDL (nmol/L)
   Baseline 17.04 (5.59) 16.88 (5.66) 16.68 (5.54)
   Change from baseline at week 12 −0.08 (0.21) 3.08 (0.21)***+++ 1.86 (0.25)***
Mean particle size (nm)
  LDL particle size
   Baseline 21.34 (0.76) 21.29 (0.75) 21.28 (0.74)
   Change from baseline at week 12 0.02 (0.03) 0.25 (0.03)*** 0.23 (0.03)***
  VLDL particle size
   Baseline 47.59 (9.29) 46.94 (9.09) 47.90 (11.61)
   Change from baseline at week 12 0.57 (0.40) 2.34 (0.40)** 1.19 (0.49)
  HDL particle size
   Baseline 9.34 (0.47) 9.33 (0.46) 9.36 (0.49)
   Change from baseline at week 12 0.01 (0.01) −0.02 (0.01)* −0.00 (0.01)
Mean levels of GlycA (µmol/L)
   Baseline 508.9 (104.6) 517.2 (114.4) 513.9 (106.4)
   Change from baseline at week 12 −13.6 (3.8) −110.9 (3.8)***+ −98.7 (4.7)*** 
Baseline data are mean (SD); change from baseline data are least squares mean (SE).
*P≤0.05; **P≤0.01; ***P≤0.001 versus placebo. +P≤0.05; ++P≤0.01; +++P≤0.001 versus adalimumab.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; RA, rheumatoid arthritis; VLDL, very-low-density lipoprotein.
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particles and decreases in the smaller LDL particles produced 
an overall mean increase at 12 weeks in LDL size for barici-
tinib (0.25 nm) and adalimumab (0.23 nm) that was significantly 
greater than placebo (0.02 nm; P=0.001) (table 2).
Total HDL particle numbers increased with statistically signif-
icant elevations in large, medium and small HDL particles for 
baricitinib and in large and small HDL particles for adalim-
umab compared with placebo (table 2). The overall impact on 
mean HDL particle size for baricitinib was a modest decrease 
at week 12 (−0.02 nm), which was not observed for adalim-
umab (0.00 nm). A statistically significant within-group increase 
from baseline in the mean very-low-density lipoprotein particle 
size was observed in baricitinib (2.34 nmol/L) and adalimumab 
(1.19 nmol/L); the increase in baricitinib 4 mg was statistically 
significant compared with placebo (0.57 nmol/L; P=0.002) 
(table 2). There were dose-dependent decreases in GlycA levels 
from baseline to week 12 in JADA (−47.30, −49.80, −58.46 and 
−80.55 µmol/L in the baricitinib 1, 2, 4 and 8 mg dose groups, 
respectively). In RA-BEAM at week 12, GlycA levels in patients 
treated with baricitinib decreased significantly compared with 
placebo or adalimumab (table 2). There were similar reductions 
in GlycA with baricitinib regardless of baseline statin use (online 
supplementary table S4).
statin use
Approximately 10% (n=221) of patients were on statin therapy 
at baseline. In the baricitinib 2/4 mg group, total cholesterol, 
LDL-C, HDL-C and triglycerides increased from baseline in 
both statin users and non-users (table 3). In the placebo group, 
total cholesterol, LDL-C, HDL-C and triglycerides remained 
essentially unchanged in non-statin users, while there was a 
modest increase from baseline in total cholesterol and LDL-C in 
statin users without much of a change in HDL-C or triglycerides 
(table 3). The interaction effect between study treatment and 
baseline statin subgroup was non-significant (P>0.1), suggesting 
that baseline statin use did not modify the effect of baricitinib 
on lipids.
Twenty patients in the placebo group, and 58 patients in the 
baricitinib 4 mg and 25 patients in the baricitinib 2 mg long-term 
cohorts initiated statin therapy after starting baricitinib and had 
lipid data available at baseline, statin initiation and the end of 
statin treatment. Figure 2 shows changes in lipid levels for these 
patients at each of these time points. The effects of statin therapy 
on LDL-C, total cholesterol, triglycerides and apolipoprotein 
B lipid levels were comparable in the baricitinib and placebo 
groups.
Cardiovascular risk scores and MACe
By baseline Framingham Risk Score, the majority of patients 
aged 30–74 years with no prior cardiovascular disease had low 
or intermediate risk in the phase III studies in each treatment 
group; less than 12% were considered high risk. There were no 
statistically significant within-group changes from baseline or 
statistically significant differences between groups (baricitinib 
4 mg, placebo or adalimumab) (table 4). For the Reynolds Risk 
Score, most non-diabetic patients aged 45–80 with no prior 
cardiovascular disease (any hsCRP status and the subgroup 
with baseline hsCRP ≤20 mg/L) had baseline scores of low or 
low-to-moderate risk in the phase III studies. Less than 13% of 
patients were considered moderate to high or high risk. There 
was a statistically significant within-group decrease in Reyn-
olds Risk Score for baricitinib groups in all three studies and 
for adalimumab in RA-BEAM as well as placebo in RA-BUILD. 
Only in RA-BEAM were the decreases significantly larger in the 
baricitinib group compared with placebo (table 4).
In the all-baricitinib RA-MACE set, 25 patients had positively 
adjudicated MACE (incidence rate=0.57 per 100 patient-years; 
patient-years of exposure=4402). There was no observed asso-
ciation between change in LDL-C and occurrence of MACE 
(online supplementary figure S3).
dIsCussIOn
RA confers increased risk of cardiovascular events that are not 
explained fully by factors that contribute to cardiovascular risk 
in the general population. This has led to the suggestion that 
inflammation mediates direct effects on cardiovascular risk in 
RA and that interventions that modulate inflammatory burden 
may favourably influence the risk of a vascular event. Specifi-
cally, MTX is associated with reduced cardiovascular mortality 
in RA.29 Tumour necrosis factor (TNF) inhibitors are similarly 
associated with reduced vascular mortality and event rates.30
Referred to as the RA lipid paradox, active disease is associ-
ated with ‘lower than expected’ cholesterol levels that in turn 
table 3 Change from baseline in lipids by baseline statin use in phase III studies up to 24 weeks with data censored at rescue
Placebo baricitinib 2/4 mg
Interaction P valuenon-statin (n=704) statin (n=84) non-statin (n=1054) statin (n=137)
Total cholesterol, mmol/L
  Baseline 5.03 (1.00) 5.13 (1.20) 5.01 (1.01) 4.88 (1.05)
  Change from baseline to week 24 −0.01 (0.03) 0.17 (0.11) 0.59 (0.02) 0.63 (0.08) 0.505
LDL-C, mmol/L
  Baseline 3.04 (0.86) 3.00 (1.08) 3.03 (0.84) 2.81 (0.85)
  Change from baseline to week 24 −0.03 (0.02) 0.20 (0.10) 0.35 (0.02) 0.41 (0.07) 0.110
HDL-C, mmol/L
  Baseline 1.56 (0.42) 1.47 (0.40) 1.57 (0.42) 1.48 (0.36)
  Change from baseline to week 24 −0.00 (0.01) 0.00 (0.03) 0.20 (0.01) 0.24 (0.02) 0.454
Triglycerides, mmol/L
  Baseline 1.38 (0.71) 1.93 (1.83) 1.38 (0.74) 1.72 (0.96)
  Change from baseline to week 24 −0.01 (0.03) −0.01 (0.12) 0.15 (0.02) 0.14 (0.09) 0.730
Baseline are mean (SD).
Change from baseline data are least squares mean (SE).
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 
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may ‘normalize’ on effective management of the inflammatory 
disease state,31 32 having several implications. First, it is difficult 
to determine the long-term impact of lipid changes in the context 
of treatment of active inflammation as in RA. For example, some 
effects of baricitinib, especially given the behaviour of the adali-
mumab control arm, likely do reflect the impact of normalisation 
of cholesterol levels. However, like tocilizumab and tofacitinib, 
the magnitude of change seems greater and more consistent for 
baricitinib than for TNF inhibitors and csDMARDs in historical 
comparator studies, and is likely to be target specific. However, 
in a recent clinical trial analysing MACE in patients with RA, no 
differences in event rates were observed when comparing tocili-
zumab with etanercept.33 In our analysis, in general, we found 
low MACE rates with no increase over time and no apparent 
association between LDL-C change and MACE at the individual 
patient level. These data are not to be overinterpreted, but they 
do reassure that no immediate clinical effect is manifest on 
lipid changes in an at-risk population—about 12% of patients 
entering these studies were already in a high-risk category on 
recruitment. In this respect, long-term observational data will 
be important across the field and distinct mechanisms of action.
Overall trends in baricitinib NMR results observed previously 
were confirmed in this analysis of phase III data from RA-BEAM, 
with a few exceptions. In the phase II JADA study, there was 
a trend towards significance for decreases of small, medium 
small and very small LDL particles at 12 weeks12; in RA-BEAM 
these differences were all significant. Also, in JADA there was no 
increase in total LDL particle number; in RA-BEAM there was 
a small, but significant, increase in total LDL particle number in 
baricitinib versus placebo and adalimumab.
One possible explanation for the mechanism by which 
baricitinib and related interventions increase LDL particle size 
could be the increased activity of lipases such as phospholipase 
A2, hepatic lipase, lipoprotein lipase and endothelial lipase, 
which are reported to be increased in chronic inflammatory 
states.34–37 Lipase levels were not investigated in this analysis, 
but it is possible that some lipases, specifically sPLA2, an acute 
phase reactant, could be reduced by an overall baricitinib-me-
diated reduction in systemic inflammation and thereby reduce 
the rate of lipoprotein remodelling. A reduction in inflamma-
tion-stimulated lipase activity could then contribute to a shift 
in the equilibrium towards larger lipoprotein particles. This 
Figure 2 Lipid profile in patients who initiated statins during the phase III studies of the six-study placebo-controlled set including data in the long-
term RA-BEYOND study for the baricitinib doses. Data are absolute values at three milestones: baseline, initiation of statin therapy and end of statin 
treatment or study period; mean (SD) for all lipids except triglycerides, which are median (25th, 75th percentiles). HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol.
table 4 Change in cardiovascular risk scores from baseline to week 24 with data censored at rescue
rA-beAM rA-buILd rA-beACOn
Placebo 
(n=488)
baricitinib
4 mg (n=487)
Adalimumab 
(n=330)
Placebo 
(n=228)
baricitinib 
2 mg (n=229)
baricitinib
4 mg (n=227)
Placebo 
(n=126)
baricitinib 
2 mg (n=127)
baricitinib 4 mg 
(n=137)
Framingham Risk Score
  Baseline 9.9 (9.9) 8.8 (9.6) 9.6 (10.0) 7.7 (6.8) 7.6 (6.4) 7.5 (6.6) 8.5 (6.3) 8.0 (6.4) 8.2 (8.0)
  Change from baseline to 
week 24
0.02 (0.19) 0.28 (0.17) −0.07 (0.21) −0.30 (0.25) 0.02 (0.22) −0.01 (0.22) −0.24 (0.39) −0.46 (0.34) 0.63 (0.32)
Reynolds Risk Score
  Baseline 5.4 (6.7) 4.5 (4.6) 5.3 (6.1) 4.7 (5.0) 3.9 (3.6) 4.4 (4.2) 5.1 (5.8) 4.3 (4.5) 4.6 (4.1)
  Change from baseline to 
week 24
−0.11 (0.16) −0.98 (0.15)*† −1.08 (0.18)*† −0.59 (0.20)‡ −0.66 (0.17)* −0.47 (0.17)† −0.32 (0.29) −0.74 (0.26)‡ −0.69 (0.26)‡
Baseline are mean (SD).
Change from baseline data are least squares mean (SE).
*Significant within-group change from baseline (P<0.001).
†Significant change from baseline versus placebo (P<0.001).
‡Significant within-group change from baseline (P<0.01).
RA, rheumatoid arthritis.
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shift in larger lipoprotein particles could reflect a reduction in 
the atherogenic potential of the overall LDL particles.
GlycA, a measure of glycosylated acute phase proteins, is an 
emerging inflammatory marker that may be useful for assessing 
disease activity and is associated with subclinical cardiovascular 
disease in patients with RA.15 19 Baricitinib decreased GlycA 
dose dependently and reductions were seen regardless of base-
line statin treatment. With recent studies suggesting GlycA as 
a marker for cardiovascular risk, these reductions in phase II 
and III studies in an RA population may portend a reduction in 
overall cardiovascular risk.
While in JADA there was no increase in LDL-C levels in 
patients on statins at baseline,12 the current analysis of pooled 
baricitinib data showed that about 10% of patients already 
receiving statins on study entry demonstrated increases in lipids. 
It is not known if increasing statin dose or changing to a more 
potent statin would reverse this effect. Meanwhile, for patients 
starting a statin during the study, total cholesterol and LDL-C 
returned to baseline levels, whereas HDL-C remained elevated. 
Consistent with these findings, reduction in elevated cholesterol 
secondary to tofacitinib has previously been reported following 
initiation of atorvastatin.38
This study has some limitations. First, the observation period 
for the placebo-controlled comparisons is short (24 weeks) 
due to the need to limit the duration of placebo treatment. 
Therefore, long-term effects of baricitinib on lipid levels are 
based on within-group comparisons only. Second, the effects 
of baseline statin use on baricitinib-induced lipid changes did 
not account for postbaseline changes in statin dose or change 
to a different statin. Also, because a limited number of patients 
initiated statin therapy during the placebo-controlled period, 
we extended the analysis for statin effect to include data from 
the LTE for patients receiving baricitinib 2 and 4 mg treatment, 
while placebo data are based on 0–24 weeks; therefore, these 
effects are based on a non-randomised comparison of patients 
starting statin treatment. As a result, caution is warranted 
when interpreting the number of patients initiating statin as 
a proxy for the number of patients who need statin therapy. 
Third, while the majority of these analyses are from pooled 
data from multiple baricitinib studies, the NMR data were 
only collected and assessed in one phase III study in MTX-IR 
patients (RA-BEAM) and therefore we could not present these 
results from the broader patient population across the baric-
itinib programme. We used the Framingham Risk Score and 
Reynolds Risk Score to characterise the change of cardiovas-
cular risk, which may not reflect well the cardiovascular risk 
in our target population given the lipid paradox in patients 
with RA. Additionally, the duration of follow-up for cardio-
vascular events in our analysis is limited to 24 weeks in the 
placebo-controlled portion of the studies and limited by the 
data cut-off date in the LTE. We continue to monitor cardio-
vascular events in extension studies.
In summary, increases in circulating lipid levels were seen 
following treatment with baricitinib that plateaued by 12 
weeks of treatment. Increases in HDL occurred across all 
particle sizes whereas LDL increases were confined to larger 
particles, with small LDL particle levels decreasing. LDL 
increases reversed in response to statin therapy. These findings 
may reflect a positive impact on aspects of the lipid paradox 
observed in RA. However, further analyses of the effects of 
baricitinib on cholesterol and lipoprotein metabolism, as well 
as continued evaluation of cardiovascular event rates during 
long-term treatment, are warranted to further characterise 
these findings and their possible clinical implications.
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